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Background: Dengue is the most rapidly spreading mosquito-
borne viral disease in the world with an estimated 50 million
dengue infections occur annually. India is one of the seven iden-
tiﬁed countries in the South-East Asia region regularly reporting
incidence of DF/DHF outbreaks and becoming major niche for
dengue infection.
Methods & Materials: History, clinical examination ﬁndings,
laboratory data, treatment details and outcome of patients with
dengue fever was collected prospectively.SD BIO LINE DENGUE
DUO (STANDARD DIGNOSTICS, KOREA) kits were utilized to diag-
nose the dengue in fection. This is a rapid diagnostic test which can
detect simultaneously NS1 and antibodies of either Types (IgM and
Ig G). Patients were categorized into Undifferentiated DF, Dengue
with Warning Signs and Severe Dengue according to WHO newer
grading.
Results: Total 148 patients were included in the study. Among
them 85(57%) were male. There were 15(10%)in Undifferentiated
DF, 45(31%) in DF with warning signs, 88(59%) in severe Dengue
respectively. Mean age of our study population was 32.75±14.99,
33.43±14.95 respectively. Mean hospital stay in study population
was 6.34±4.66 days. Rashwas found in 47 (37.76%), hepatomegaly
in 23 (15%) and splenomegaly seen in 25(16%) patients. Bleeding
manifestationswere seen 61(41%) patients in total study group, out
ofwhichmalenawas seen in33(22%)patients, gumbleeding, hema-
turia, hematemesis, hemoptysis and epistaxis seen in 6(4%), 7(5%),
4(3%), 3(2%) and 3(2%) patients respectively. Intracranial bleed as
bleeding manifestation was seen 2(1%) patients one SDH and one
case of intracerebral bleed, both non traumatic. Mean hemoglobin
(g/dl) for was 13.5±2.6g/dl. Hypoalbuminemia (<3.5 g/dl) was
seen in 62(42%) patients with the mean value of 2.8±g/dl. Chest
roentgenographic abnormalities found in 38(26%) patients of the
study population. Pleural effusion was found in 31(19%) patients.
Acalculous cholecystitis on ultrasonogram was seen in 18(12%)
patients in our study population. NS1 antigen was detected in 80
(54%). Mortality was noted in 3.3% of the study population.
Conclusion: Out of 148 patients, majority consisted of severe
dengue infection. Elevated transaminases were seen in 136 (92%)
patients. Mortality was noted in 5(3.3)% of the study population.
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Multiple siRNAs against HCV and host genes are
more effective in inhibition of HCV replication
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Background: Hepatitis C virus is a major cause of chronic liver
diseases such as chronic hepatitis, liver cirrhosis and hepatocel-
lular carcinoma. The present available anti-HCV drugs, Pegylated
interferon- (IFN- ) and Ribavirin have limited efﬁcacy, resis-
tance problems and high manufacturing cost. Among the newer
approaches to curb the viral replication, RNA interference (RNAi)
based approaches have shown tremendous prospective to inhibit
HCV replication.
Methods & Materials: pFL-J6/JFH1 vector was linearized with
Xbal and subjected to in vitro transcription. TheHCV genomic repli-
